LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. - Wikidata - wikimedia - TriplyDB

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q33931637

about

Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ Abnormal Activation of BMP Signaling Causes Myopathy in Fbn2 Null Mice Myofibroblasts: trust your heart and let fate decide.Modifier genes and their effect on Duchenne muscular dystrophy 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands Biochemical and Functional Comparisons of mdx and Sgcg(-/-) Muscular Dystrophy Mouse Models.Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity.Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.Genetic Modifiers for Neuromuscular Diseases Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.Latent transforming growth factor binding protein 4 regulates transforming growth factor beta receptor stability.Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies.Genotype-Specific Interaction of Latent TGFβ Binding Protein 4 with TGFβ.Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption.Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype.Effect of genetic background on the dystrophic phenotype in mdx mice.The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.A Common Variant of PROK1 (V67I) Acts as a Genetic Modifier in Early Human Pregnancy through Down-Regulation of Gene Expression.Modifying muscular dystrophy through transforming growth factor-β.DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy.Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.Circulating Biomarkers for Duchenne Muscular Dystrophy.Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy.Modifiers of heart and muscle function: where genetics meets physiology.Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.Prospect for pharmacological therapies to treat skeletal muscle dysfunction.

P2860

Q26795772-D7742696-92FD-41D2-993A-480D41A94EEE Q27308903-D0D790E3-74F3-46CF-9BE5-985D48715469 Q27310854-F2044219-F3D7-4830-9FDD-FFAE075980C0 Q27692541-06BF4363-EDB8-4F04-A04B-6E81D33179CA Q28083441-47A51963-AF3E-43EC-A6F0-168C3CD00AC0 Q28611318-E00B8C58-37F0-4740-BB78-D47FCE6503E4 Q30650746-F2888CFE-B675-47EA-8722-8D4379DF789D Q30856806-6BA8BC18-8795-4030-ACBE-15ED70733115 Q31056857-666DCDB7-6EDD-4719-868B-E74E30A39949 Q34332718-64165A1A-E886-428B-B843-00E6139CE97F Q34341005-530827EB-E2DF-4C64-B7AC-5850508282E4 Q34356389-63229300-5856-4912-919F-D58FB6CDE676 Q34424160-291FEC8B-FAF0-4A7C-A418-FE2028F8FED4 Q35009178-A72BD65F-51DB-4D9E-8B91-F457847133DE Q35119976-C3AC8B30-09E0-4C0F-AA7B-1979EE549711 Q35495274-82D21FD4-31B2-4445-8BC5-A4366DDC0D49 Q35630212-14FA1DC5-4E79-4CC6-B29F-9101AFEE894D Q35766401-40EE4B2C-E58C-4E51-89D7-EF416BA4F4B3 Q35826211-71C4007E-3909-4B3E-8D19-D72AF2BFF6C4 Q35903229-A05C386B-EFA2-4AC3-84AE-044C257800CC Q35937127-47E0D3E0-D96A-4202-88D0-B1216F9378D0 Q35987272-6611D583-3A6D-49C4-A5B3-C89934174081 Q36109634-96347112-CDED-46A7-B7C6-A3B39C883A5A Q36150125-D0762E3A-4101-4C2E-8E03-33125EE1CAEF Q36151477-7F803586-7C96-47C0-A416-C3BBF0E554BD Q36155677-CCD0D6E4-9B57-489D-85B1-4271627CA4D1 Q36344905-F224F155-CDE4-48D6-A5C1-C03D4A10B102 Q36402584-69311C6D-16B4-4BB4-B714-741847D4319D Q36577433-EEA0C608-2E83-4CA8-9528-682B959FF4AE Q36666959-645BBDFD-26A0-46EF-A12F-81C1D6EBF778 Q37064241-450F2FDF-D7F6-49B3-A955-596EDB4D47F1 Q37158951-4747821A-19C9-4B7E-AFCC-62C9CDE7EA19 Q37396900-8F3C351D-6375-429A-9C5B-583E8812A11B Q37474934-7B23BB8C-512A-4E7E-9172-A396820EE68E Q37589614-B146DD04-CE36-42E8-8151-4B91FCAA3223 Q37610530-595BBBC1-498D-4D20-9A1F-3F55B3A402F0 Q37622616-B4A78E03-B746-4201-A898-465691E7F610 Q38161422-37CB2D51-122C-4854-8804-10A5F899A35B Q38168509-6C4B0426-4CFF-43F9-929C-85DA1276C67E Q38264369-052DF5CB-168F-45BC-A646-9B614D29DCF3

P2860

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q33931637

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@ast

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@en

type

label

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@ast

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@en

prefLabel

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@ast

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@en

P1433

Q33931637-8F13E994-17F2-4560-94FD-19EFCEC48D0F

P1476

Q33931637-78128C83-EADD-4DAC-A2C8-A05FC767A901

P2093

Q33931637-17EC7AF8-52A1-41C0-8123-7BB2F776FEAE

Q33931637-2E230F62-695E-4B86-AD90-B4FC454815B7

Q33931637-3C3B374C-5CD1-451E-8FEB-D7C2B5659B11

Q33931637-3EB3DD49-F6B7-43A2-9D29-B2521099D02E

Q33931637-405B3F8D-499C-4A71-965E-8112276470F7

Q33931637-481BA855-CCBA-4865-B60F-C70C6F82993E

Q33931637-4BD2F365-47B0-4D68-8101-E2906CF067BB

Q33931637-5DDE3FC4-7CF0-494F-9183-09C294F4C61D

Q33931637-66262590-EE86-484D-ACB4-A1DBA36105B7

Q33931637-9872AE30-A81F-4386-9542-873674BA746B

P2860

Q33931637-176CDECF-FA23-4225-B9E7-066B7A5763C4

Q33931637-28509AD0-381C-42A4-A059-B228E4D85933

Q33931637-35616138-B1C7-4183-A627-C265D7F8325E

Q33931637-424BEE38-9379-4A1E-9CDB-64A0E4EC25C9

Q33931637-43958A2E-5BB3-488F-ACC4-3781BA63A47B

Q33931637-453602A8-C80B-4D3D-80E2-EBB51F065F29

Q33931637-5BD78C58-21ED-45F0-A6E2-136DD928950E

Q33931637-5C3A0411-B98D-4BFC-A6E9-774173677F9A

Q33931637-5CA112F8-C004-45CE-AEB5-D4ACEDC20046

Q33931637-66D9A55B-71DB-4D4A-B216-8303FEF41A2D

P304

Q33931637-0AE3891B-6F87-4B3B-9254-0A84426A4F85

P31

Q33931637-1C7A9399-A3CC-436E-A567-2FA85A58DF01

P356

Q33931637-BF1AA6B2-C426-4F0C-89D4-B47CAF341E45

P433

Q33931637-7A0D4DB4-51D1-4ACA-8925-8F338BA82B2B

P478

Q33931637-E8F64233-3CAB-4C94-80AD-DE1FAC1A95E0

P50

Q33931637-459613C3-7E49-4976-906A-C20A9EF0E46B

Q33931637-777BDF3D-D900-4262-AF4D-13B292DFBF40

Q33931637-B8FA478F-3A65-4D01-B551-E268D173288B

Q33931637-BCAE54C1-1E49-4C32-8C4B-82E3654AA06E

Q33931637-FB3E0818-DE41-46AB-A72F-44059B0142E4

P577

Q33931637-EFA59F93-FFA8-4A95-9123-B07FE7D85696

P698

Q33931637-F98D75DC-4D5C-4876-847F-069689FB087C

P932

Q33931637-EEB27645-B6E0-48E4-8CD5-6A4AA888507C

P356

P1433

Annals of Neurology

P1476

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

@en

P2093

Alan Pestronk

http://www.w3.org/2001/XMLSchema#string

Diane M Dunn

http://www.w3.org/2001/XMLSchema#string

Eduard Gappmaier

http://www.w3.org/2001/XMLSchema#string

Elizabeth M McNally

http://www.w3.org/2001/XMLSchema#string

Ermelinda Ceco

http://www.w3.org/2001/XMLSchema#string

Jerry R Mendell

http://www.w3.org/2001/XMLSchema#string

John W Day

http://www.w3.org/2001/XMLSchema#string

Julaine M Florence

http://www.w3.org/2001/XMLSchema#string

Michael T Howard

http://www.w3.org/2001/XMLSchema#string

Richard S Finkel

http://www.w3.org/2001/XMLSchema#string

P2860

Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

A map of human genome variation from population-scale sequencing

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation

A method and server for predicting damaging missense mutations

TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements

SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy

Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.

Distinct genetic regions modify specific muscle groups in muscular dystrophy.

P304

481-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.23819

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Kevin M. Flanigan

Craig M. McDonald

Kay-Marie Lamar

Katherine Mathews

Kathryn J Swoboda

P577

2013-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23440719

http://www.w3.org/2001/XMLSchema#string

P932

4106425

http://www.w3.org/2001/XMLSchema#string